细胞癌-话题@MedSci

#细胞癌#

1086篇内容 | 2820人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1979075, encodeId=2ace19e9075b1, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=ASCO GU 2021: 转移性肾细胞癌一线采用免疫治疗效果如何？, objectType=article, longId=207195, objectId=8fad20e19548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fad20e19548, replyNumber=0, likeNumber=63, createdTime=2021-06-27, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fad20e19548, moduleTitle=ASCO GU 2021: 转移性肾细胞癌一线采用免疫治疗效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fad20e19548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979127, encodeId=66cc19e91277a, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估, objectType=article, longId=211606, objectId=ff0121160699, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff0121160699, replyNumber=0, likeNumber=62, createdTime=2022-04-21, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff0121160699, moduleTitle=Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff0121160699)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979278, encodeId=5b7119e927875, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Front Oncol：PD-L1高表达是肝细胞癌患者手术切除后索拉非尼辅助治疗后复发的独立预测因素, objectType=article, longId=294335, objectId=1c8d29433575, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c8d29433575, replyNumber=0, likeNumber=68, createdTime=2022-05-31, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c8d29433575, moduleTitle=Front Oncol：PD-L1高表达是肝细胞癌患者手术切除后索拉非尼辅助治疗后复发的独立预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c8d29433575)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979079, encodeId=f42719e9079ea, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Lancet：舒尼替尼与三种MET激酶抑制剂用于转移性乳头状肾细胞癌的疗效对比, objectType=article, longId=207346, objectId=f9b820e346bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9b820e346bb, replyNumber=0, likeNumber=65, createdTime=2021-12-07, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9b820e346bb, moduleTitle=Lancet：舒尼替尼与三种MET激酶抑制剂用于转移性乳头状肾细胞癌的疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9b820e346bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979186, encodeId=8c7019e918677, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Int J Urol：非转移性pT3a肾细胞癌的术后复发预测因素调查 , objectType=article, longId=216723, objectId=55de216e2336, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55de216e2336, replyNumber=0, likeNumber=72, createdTime=2021-11-03, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55de216e2336, moduleTitle=Int J Urol：非转移性pT3a肾细胞癌的术后复发预测因素调查 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55de216e2336)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979211, encodeId=cf8819e921147, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Front Oncol：肝硬化严重程度对肝细胞癌患者进行手术(LR)和微波消融(PMCT)治疗的影响, objectType=article, longId=218300, objectId=ec13218300e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec13218300e1, replyNumber=0, likeNumber=74, createdTime=2021-12-21, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec13218300e1, moduleTitle=Front Oncol：肝硬化严重程度对肝细胞癌患者进行手术(LR)和微波消融(PMCT)治疗的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec13218300e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979253, encodeId=2eaf19e925316, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Clin Cancer Res：晚期肾细胞癌患者免疫治疗停药后的无治疗生存期（TFS）：Check- Mate 214研究, objectType=article, longId=221415, objectId=e7312214158c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7312214158c, replyNumber=0, likeNumber=113, createdTime=2022-04-19, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7312214158c, moduleTitle=Clin Cancer Res：晚期肾细胞癌患者免疫治疗停药后的无治疗生存期（TFS）：Check- Mate 214研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7312214158c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979230, encodeId=0b7a19e9230ac, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Hepatology International：索拉非尼- TACE治疗后难治性不可切除肝细胞癌(HCC)续贯使用阿帕替尼的疗效, objectType=article, longId=219974, objectId=ad462199e46a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad462199e46a, replyNumber=0, likeNumber=62, createdTime=2022-05-11, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad462199e46a, moduleTitle=Hepatology International：索拉非尼- TACE治疗后难治性不可切除肝细胞癌(HCC)续贯使用阿帕替尼的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad462199e46a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979166, encodeId=78f419e91668c, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Clin Cancer Res：预测仑伐替尼（Lenvatinib）在不可切除肝细胞癌中生存获益的药效学生物标志物:来自III期REFLECT研究, objectType=article, longId=214268, objectId=9fbc2142681c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fbc2142681c, replyNumber=0, likeNumber=58, createdTime=2022-05-04, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fbc2142681c, moduleTitle=Clin Cancer Res：预测仑伐替尼（Lenvatinib）在不可切除肝细胞癌中生存获益的药效学生物标志物:来自III期REFLECT研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fbc2142681c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979094, encodeId=88a819e909434, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Eur Radiol:如何可靠地预测经索拉非尼治疗的晚期肝细胞癌生存率, objectType=article, longId=208195, objectId=2b4e208195f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b4e208195f6, replyNumber=0, likeNumber=64, createdTime=2021-03-25, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b4e208195f6, moduleTitle=Eur Radiol:如何可靠地预测经索拉非尼治疗的晚期肝细胞癌生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b4e208195f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979165, encodeId=a21319e9165d1, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Liver Cancer：雷莫芦单抗（Ramucirumab）治疗甲胎蛋白升高的中期肝细胞癌（HCC）患者的疗效:来自两项3期研究(REACH和REACH-2)的汇总结果, objectType=article, longId=214189, objectId=ceaa214189f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ceaa214189f7, replyNumber=0, likeNumber=53, createdTime=2022-02-19, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ceaa214189f7, moduleTitle=Liver Cancer：雷莫芦单抗（Ramucirumab）治疗甲胎蛋白升高的中期肝细胞癌（HCC）患者的疗效:来自两项3期研究(REACH和REACH-2)的汇总结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ceaa214189f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979371, encodeId=3ea619e937130, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=【PHILIPS每日一例】肝脏原发性鳞状细胞癌一例, objectType=article, longId=290192, objectId=8e1b29019298, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e1b29019298, replyNumber=0, likeNumber=57, createdTime=2022-03-05, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e1b29019298, moduleTitle=【PHILIPS每日一例】肝脏原发性鳞状细胞癌一例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e1b29019298)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979107, encodeId=12ea19e910705, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=NEJM ：乐伐替尼-派姆单抗治疗晚期肾细胞癌效果优于舒尼替尼, objectType=article, longId=209719, objectId=aeac209e1906, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aeac209e1906, replyNumber=0, likeNumber=77, createdTime=2022-03-18, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aeac209e1906, moduleTitle=NEJM ：乐伐替尼-派姆单抗治疗晚期肾细胞癌效果优于舒尼替尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aeac209e1906)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979126, encodeId=cd0919e912615, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Liver Cancer：仑伐替尼（Lenvatinib）治疗晚期肝细胞癌（HCC）失败后的小分子靶向药物治疗的选择, objectType=article, longId=211561, objectId=4f32211561f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f32211561f9, replyNumber=0, likeNumber=64, createdTime=2022-03-06, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f32211561f9, moduleTitle=Liver Cancer：仑伐替尼（Lenvatinib）治疗晚期肝细胞癌（HCC）失败后的小分子靶向药物治疗的选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f32211561f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979164, encodeId=a19c19e91647f, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Eur Urol：单独使用舒尼替尼或在肾切除术后使用舒尼替尼治疗转移性肾细胞癌患者 , objectType=article, longId=214148, objectId=0c7921414807, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c7921414807, replyNumber=0, likeNumber=72, createdTime=2022-03-07, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c7921414807, moduleTitle=Eur Urol：单独使用舒尼替尼或在肾切除术后使用舒尼替尼治疗转移性肾细胞癌患者 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c7921414807)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979153, encodeId=238919e915340, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Liver Cancer：卡博替尼（Cabozantinib）治疗不可手术切除肝细胞癌的疗效和安全性：真实世界研究结果, objectType=article, longId=213115, objectId=9d6a213115e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d6a213115e4, replyNumber=0, likeNumber=85, createdTime=2021-12-04, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d6a213115e4, moduleTitle=Liver Cancer：卡博替尼（Cabozantinib）治疗不可手术切除肝细胞癌的疗效和安全性：真实世界研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d6a213115e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979202, encodeId=aeb719e9202cb, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=JAMA：卡培他滨用于治疗和预防日光性角化、鳞状细胞癌和基底细胞癌的评估, objectType=article, longId=217754, objectId=905c21e754d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=905c21e754d2, replyNumber=0, likeNumber=126, createdTime=2021-12-03, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=905c21e754d2, moduleTitle=JAMA：卡培他滨用于治疗和预防日光性角化、鳞状细胞癌和基底细胞癌的评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=905c21e754d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979074, encodeId=08cd19e907491, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=GUT：HBV整合促进肝细胞癌局部及远距离致癌驱动因子的改变, objectType=article, longId=207042, objectId=aaa020e042e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aaa020e042e3, replyNumber=0, likeNumber=82, createdTime=2021-07-26, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aaa020e042e3, moduleTitle=GUT：HBV整合促进肝细胞癌局部及远距离致癌驱动因子的改变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aaa020e042e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979187, encodeId=c20f19e9187a2, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Liver Cnacer：mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌的疗效和安全性：II期临床研究, objectType=article, longId=216786, objectId=af4a216e8623, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af4a216e8623, replyNumber=0, likeNumber=86, createdTime=2022-03-06, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af4a216e8623, moduleTitle=Liver Cnacer：mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌的疗效和安全性：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af4a216e8623)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1979215, encodeId=2e6a19e921583, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, objectTitle=Eur J Cancer: 卡博替尼（Cabozantinib）治疗转移性肾细胞癌的疗效：来自真实世界研究CABOREAL结果分析, objectType=article, longId=219150, objectId=a7ac21915026, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7ac21915026, replyNumber=0, likeNumber=84, createdTime=2021-12-15, rootId=0, userName=qingting, userId=e457184, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7ac21915026, moduleTitle=Eur J Cancer: 卡博替尼（Cabozantinib）治疗转移性肾细胞癌的疗效：来自真实世界研究CABOREAL结果分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7ac21915026)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

细胞癌

2020-05-29

qingting (审核中...)

前往app查看评论内容

#细胞癌#

ASCO GU 2021: 转移性肾细胞癌一线采用免疫治疗效果如何？

2021-06-27

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估

2022-04-21

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Front Oncol：PD-L1高表达是肝细胞癌患者手术切除后索拉非尼辅助治疗后复发的独立预测因素

2022-05-31

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Lancet：舒尼替尼与三种MET激酶抑制剂用于转移性乳头状肾细胞癌的疗效对比

2021-12-07

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Int J Urol：非转移性pT3a肾细胞癌的术后复发预测因素调查

2021-11-03

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Front Oncol：肝硬化严重程度对肝细胞癌患者进行手术(LR)和微波消融(PMCT)治疗的影响

2021-12-21

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Clin Cancer Res：晚期肾细胞癌患者免疫治疗停药后的无治疗生存期（TFS）：Check- Mate 214研究

2022-04-19

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Hepatology International：索拉非尼- TACE治疗后难治性不可切除肝细胞癌(HCC)续贯使用阿帕替尼的疗效

2022-05-11

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Clin Cancer Res：预测仑伐替尼（Lenvatinib）在不可切除肝细胞癌中生存获益的药效学生物标志物:来自III期REFLECT研究

2022-05-04

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Eur Radiol:如何可靠地预测经索拉非尼治疗的晚期肝细胞癌生存率

2021-03-25

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Liver Cancer：雷莫芦单抗（Ramucirumab）治疗甲胎蛋白升高的中期肝细胞癌（HCC）患者的疗效:来自两项3期研究(REACH和REACH-2)的汇总结果

2022-02-19

qingting (审核中...)

前往app查看评论内容

#细胞癌#

【PHILIPS每日一例】肝脏原发性鳞状细胞癌一例

2022-03-05

qingting (审核中...)

前往app查看评论内容

#细胞癌#

NEJM ：乐伐替尼-派姆单抗治疗晚期肾细胞癌效果优于舒尼替尼

2022-03-18

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Liver Cancer：仑伐替尼（Lenvatinib）治疗晚期肝细胞癌（HCC）失败后的小分子靶向药物治疗的选择

2022-03-06

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Eur Urol：单独使用舒尼替尼或在肾切除术后使用舒尼替尼治疗转移性肾细胞癌患者

2022-03-07

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Liver Cancer：卡博替尼（Cabozantinib）治疗不可手术切除肝细胞癌的疗效和安全性：真实世界研究结果

2021-12-04

qingting (审核中...)

前往app查看评论内容

#细胞癌#

JAMA：卡培他滨用于治疗和预防日光性角化、鳞状细胞癌和基底细胞癌的评估

2021-12-03

qingting (审核中...)

前往app查看评论内容

#细胞癌#

GUT：HBV整合促进肝细胞癌局部及远距离致癌驱动因子的改变

2021-07-26

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Liver Cnacer：mTOR抑制剂Temsirolimus联合索拉非尼治疗晚期肝细胞癌的疗效和安全性：II期临床研究

2022-03-06

qingting (审核中...)

前往app查看评论内容

#细胞癌#

Eur J Cancer: 卡博替尼（Cabozantinib）治疗转移性肾细胞癌的疗效：来自真实世界研究CABOREAL结果分析

2021-12-15

科室
- - 订阅+
  - 更多科室
工具
服务